Which approach helps achieve the goal of lowest dose with max benefit and lowest toxicity risk?

Which approach helps achieve the goal of lowest dose with max benefit and lowest toxicity risk?

• A. Therapeutic drug monitoring
• B. Genetic profiling
• C. Routine imaging
• D. Empirical escalation strategy

Answer: (A)

Therapeutic drug monitoring involves measuring drug levels in the patient’s blood and adjusting the dose to keep those levels within a target therapeutic window. This direct link between exposure and effect lets you tailor dosing to the individual, so you use the smallest dose that achieves the desired benefit while minimizing toxicity. By routinely checking concentrations (often trough levels) and considering kidney and liver function, drug interactions, age, weight, and illness, dose can be fine-tuned to maximize efficacy and reduce adverse effects. While genetic profiling can influence how a drug is processed, it doesn’t replace the real-time information provided by monitoring actual drug exposure. Routine imaging monitors disease status rather than dose, and an empirical escalation strategy increases exposure without accounting for individual pharmacokinetics and safety.

Therapeutic drug monitoring involves measuring drug levels in the patient’s blood and adjusting the dose to keep those levels within a target therapeutic window. This direct link between exposure and effect lets you tailor dosing to the individual, so you use the smallest dose that achieves the desired benefit while minimizing toxicity. By routinely checking concentrations (often trough levels) and considering kidney and liver function, drug interactions, age, weight, and illness, dose can be fine-tuned to maximize efficacy and reduce adverse effects. While genetic profiling can influence how a drug is processed, it doesn’t replace the real-time information provided by monitoring actual drug exposure. Routine imaging monitors disease status rather than dose, and an empirical escalation strategy increases exposure without accounting for individual pharmacokinetics and safety.